298. Hereditary pancreatitis Clinical trials / Disease details
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05270434 (ClinicalTrials.gov) | March 1, 2022 | 10/1/2022 | Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. | Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Pancreatitis With Pancreatic Stones. | Pancreatitis, Chronic | Procedure: time interval between ESWL and ERCP is 12h;Procedure: time interval between ESWL and ERCP is 12-36h;Procedure: time interval between ESWL and ERCP is greater than 36h;Drug: morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics) | Changhai Hospital | NULL | Not yet recruiting | 18 Years | 75 Years | All | 225 | N/A | China |